Comprehensive literature review of monkeypox

Ma'mon M Hatmal, Mohammad A I Al-Hatamleh, Amin N Olaimat, Suhana Ahmad, Hanan Hasan, Nurfatihah Azlyna Ahmad Suhaimi, Khaled A Albakri, Anas Abedalbaset Alzyoud, Ramlah Kadir, Rohimah Mohamud, Ma'mon M Hatmal, Mohammad A I Al-Hatamleh, Amin N Olaimat, Suhana Ahmad, Hanan Hasan, Nurfatihah Azlyna Ahmad Suhaimi, Khaled A Albakri, Anas Abedalbaset Alzyoud, Ramlah Kadir, Rohimah Mohamud

Abstract

The current outbreak of monkeypox (MPX) infection has emerged as a global matter of concern in the last few months. MPX is a zoonosis caused by the MPX virus (MPXV), which is one of the Orthopoxvirus species. Thus, it is similar to smallpox caused by the variola virus, and smallpox vaccines and drugs have been shown to be protective against MPX. Although MPX is not a new disease and is rarely fatal, the current multi-country MPX outbreak is unusual because it is occurring in countries that are not endemic for MPXV. In this work, we reviewed the extensive literature available on MPXV to summarize the available data on the major biological, clinical and epidemiological aspects of the virus and the important scientific findings. This review may be helpful in raising awareness of MPXV transmission, symptoms and signs, prevention and protective measures. It may also be of interest as a basis for performance of studies to further understand MPXV, with the goal of combating the current outbreak and boosting healthcare services and hygiene practices.Trial registration: ClinicalTrials.gov identifier: NCT02977715..Trial registration: ClinicalTrials.gov identifier: NCT03745131..Trial registration: ClinicalTrials.gov identifier: NCT00728689..Trial registration: ClinicalTrials.gov identifier: NCT02080767..

Keywords: MPX; MPXV; Monkeypox; emerging infectious diseases; viral outbreak.

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
General structure of the MPXV genome. The genome is made up of double-stranded linear DNA (approximately 197 kb), primarily composed of hairpin loops, some open reading frames (ORFs), and tandem repeats, while the ITRs are made up of tandem repeats, hairpin loops, and some ORFs [13]. The ends of the genome form direct repeats called ITRs, and the genome has a terminal hairpin loop (no free ends). Most of the essential genes are located in the central part of the genome, and there are ∼250 genes in the genome [14]. The upper box reveals a 625-bp deletion directly upstream of the right ITR (red box), which completely removes MPV-Z-N2R (locus 201) and truncates OMCP (MPV-Z-N3R, locus 202). The central part contains the following genes: D1R: large subunit of mRNA capping enzyme, D2R and D3R: internal structural proteins of intracellular mature virions (IMVs), D4R: viral DNA glycosylase, D5R: ATPase, D6R: subunit of early transcription protein, D7R: subunit of RNA polymerase, D8R: membrane protein of IMV, D9R, D10R, D11R: nucleotide triphosphate phosphorylate, D12R: small subunit of mRNA capping enzyme, and D13R: core protein of IMV [14].
Figure 2.
Figure 2.
Steps of MPXV entry into host cells [13,14,59–62]. (1) Schematic of the structure of MPXV. (2) Both the EEV and IMV virions penetrate the host membrane by binding and macropinocytosis. MPXV virions use glycosaminoglycans as host receptors. (3) After the internal virion components enter the cytoplasm, core uncoating occurs and this process leads to delivery of the MPXV genome and accessory proteins to the cytosol. (4) The released MPXV genome is used as a template for DNA replication. (5) Early viral DNA transcription followed by translation into the host ribosome occurs to encode essential proteins. Early proteins aid in DNA replication. (6) These proteins interact with host sensor proteins resulting in internal and external modulations. The major intracellular modulations include prevention of viral genome detection, induction of cell cycle arrest, apoptosis inhibition, inhibition of the antiviral system and modulation of some host cellular signalling pathways. Early proteins play essential extracellular roles as immunomodulatory agents and as growth factor-like domains that stimulate onset of mitosis in neighbouring cells. (7) Early proteins are used in production of intermediate proteins. (8) These proteins are involved in late transcription and translation processes and aid in DNA replication. (9) Late proteins are essential components for viral assembly. (10) Viral morphogenesis occurs by formation of inner tubular nucleocapsid structure folding and assembly of viral glycoproteins to generate MV virions. (11) Except those released via infected cell lysis, MV virions transit to the Golgi apparatus along microtubules for double membrane wrapping. (12) The resulting EEV virions exit the infected cell by two routes: by the actin tail assembly, which provides enough force to propel the virions out of the cell or by budding from a cellular membrane (Created with BioRender.com).
Figure 3.
Figure 3.
MPXV proteins (red) that participate in virostealth, viromimicry and virotransduction are responsible for immune evasion mechanisms of MPX infection [134–137]. In viromimicry, MPXV mimics host receptors that inhibit binding of IFN, IL-1β and TNF as well as MPXV-encoded chemokines and growth factors. In virotransduction, several antiviral pathways including IFN, NF-κB, IRF3 and apoptosis are interfered with by intracellular MPXV-encoded proteins to inhibit their functions. Virostealth is achieved with F1, an anti-apoptotic host range protein that helps with viral replication and the spread of MPX infection (Created with BioRender.com).
Figure 4.
Figure 4.
Common symptoms of MPX according to the WHO [160] (Created with BioRender.com).
Figure 5.
Figure 5.
Transmission routes associated with MPXV according to the WHO [160] (Created with BioRender.com).
Figure 6.
Figure 6.
Histology and negative-stain electron microscopic views of MPXV virions (Created with BioRender.com).

References

    1. Ladnyj ID, Ziegler P, Kima E.. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593–597.
    1. Foster SO, Brink EW, Hutchins DL, et al. . Human monkeypox. Bull World Health Organ. 1972;46(5):569–576.
    1. Likos AM, Sammons SA, Olson VA, et al. . A tale of two clades: monkeypox viruses. J Gen Virol. 2005;86(10):2661–2672.
    1. Sklenovská N, Van Ranst M.. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health. 2018;6:241.
    1. Li Y, Zhao H, Wilkins K, et al. . Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods. 2010;169(1):223–227.
    1. Maksyutov RA, Gavrilova EV, Shchelkunov SN.. Species-specific differentiation of variola, monkeypox, and varicella-zoster viruses by multiplex real-time PCR assay. J Virol Methods. 2016;236:215–220.
    1. Simpson K, Heymann D, Brown CS, et al. . Human monkeypox – after 40 years, an unintended consequence of smallpox eradication. Vaccine. 2020;38(33):5077–5081.
    1. Epidemiological Update Monkeypox in non-endemic countries - 13 June 2022: PAHO/WHO; [19 June 2022]. Available from:
    1. Shchelkunov SN, Totmenin AV, Safronov PF, et al. . Analysis of the monkeypox virus genome. Virology. 2002;297(2):172–194.
    1. Wittek R, Moss B.. Tandem repeats within the inverted terminal repetition of vaccinia virus DNA. Cell. 1980;21(1):277–284.
    1. Garon CF, Barbosa E, Moss B.. Visualization of an inverted terminal repetition in vaccinia virus DNA. Proc Natl Acad Sci USA. 1978;75(10):4863–4867.
    1. Wittek R, Menna A, Müller HK, et al. . Inverted terminal repeats in rabbit poxvirus and vaccinia virus DNA. J Virol. 1978;28(1):171–181.
    1. Sklenovská N. Monkeypox virus. In: Malik YS, Singh RK, Dhama K, editors. Animal-origin viral zoonoses. Singapore: Springer; 2020. p. 39–68.
    1. Harrison SC, Alberts B, Ehrenfeld E, et al. . Discovery of antivirals against smallpox. Proc Natl Acad Sci USA. 2004;101(31):11178–11192.
    1. Hendrickson RC, Wang C, Hatcher EL, et al. . Orthopoxvirus genome evolution: the role of gene loss. Viruses. 2010;2(9):1933–1967.
    1. Kugelman JR, Johnston SC, Mulembakani PM, et al. . Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerg Infect Dis. 2014;20(2):232–239.
    1. Elde NC, Child SJ, Eickbush MT, et al. . Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell. 2012;150(4):831–841.
    1. Barrett JW, McFadden G.. Origin and evolution of poxviruses. In: Domingo E, Parrish CR, Holland JJ, editors. Origin and evolution of viruses. Elsevier; 2008. p. 431–446.
    1. Fenner F. The orthopoxviruses. Elsevier; 2012.
    1. Jahrling PB, Huggins JW, Ibrahim MS, et al. . Smallpox and related orthopoxviruses. Medical aspects of biological warfare. Washington (DC: ): TMM Publications, Office of The Surgeon General; 2007. p. 215–240.
    1. Esposito JJ, Knight JC.. Orthopoxvirus DNA: a comparison of restriction profiles and maps. Virology. 1985;143(1):230–251.
    1. Takemura M. Poxviruses and the origin of the eukaryotic nucleus. J Mol Evol. 2001;52(5):419–425.
    1. Moss B. The molecular biology of poxviruses. In: Bercoff RP, editor. The molecular basis of viral replication. Boston, MA: Springer; 1987. p. 499–516.
    1. Fenner F. The eradication of smallpox. Prog Med Virol. 1977;23:1–21.
    1. Marennikova S, Šeluhina EM, Mal’Ceva N, et al. . Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bull World Health Organ. 1972;46(5):599.
    1. Noble J Jr. A study of New and Old World monkeys to determine the likelihood of a simian reservoir of smallpox. Bull World Health Organ. 1970;42(4):509.
    1. Douglass N, Dumbell K.. Independent evolution of monkeypox and variola viruses. J Virol. 1992;66(12):7565–7567.
    1. Hutin YJF, Williams RJ, Malfait P, et al. . Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis. 2001;7(3):434–438.
    1. Heymann DL, Szczeniowski M, Esteves K.. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1998;54(3):693–702.
    1. Esposito JJ, Knight JC.. Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses. Virology. 1984;135(2):561–567.
    1. Bugert JJ, Darai G.. Poxvirus homologues of cellular genes. Virus Genes. 2000;21(1):111–133.
    1. Shchelkunov SN, Totmenin AV, Babkin IV, et al. . Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 2001;509(1):66–70.
    1. Chen N, Li G, Liszewski MK, et al. . Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology. 2005;340(1):46–63.
    1. Alcoba-Florez J, Muñoz-Barrera A, Ciuffreda L, et al. A draft of the first genome sequence of Monkeypox virus associated with the multi-country outbreak in May 2022 from the Canary Islands, Spain: Virological; 2022 [24 June 2022]. Available from:
    1. Zorec TM, Zakotnik S, Suljič A, et al. First 2022 monkeypox outbreak genome sequences from Slovenia: Virological; 2022 [24 June 2022]. Available from:
    1. Gruber CEM, Giombini E, Mazzotta V, et al. First available Monkeypox genome sequence from the first case in Italy related to multi-country outbreak in May 2022: Virological; 2022 [24 June 2022]. Available from:
    1. Destras G, Bal A, Simon B, et al. Illumina whole-genome sequence of Monkeypox virus in a patient travelling from the Canary Islands to France: Virological; 2022 [28 June 2022]. Available from:
    1. Selhorst P, Rezende AM, Block T, et al. Belgian case of Monkeypox virus linked to outbreak in Portugal: Virological; 2022 [24 June 2022]. Available from:
    1. Claro IM, Romano CM, Candido DDS, et al. . Shotgun metagenomic sequencing of the first case of monkeypox virus in Brazil, 2022. Rev Inst Med Trop Sao Paulo. 2022;64:e48.
    1. Antwerpen MH, Lang D, Zange S, et al. First German genome sequence of Monkeypox virus associated to multi-country outbreak in May 2022: Virological; 2022 [24 June 2022]. Available from:
    1. Isidro J, Borges V, Pinto M, et al. Multi-country outbreak of Monkeypox virus: genetic divergence and first signs of microevolution: Virological; 2022 [24 June 2022]. Available from:
    1. Isidro J, Borges V, Pinto M, et al. First draft genome sequence of Monkeypox virus associated with the suspected multi-country outbreak, May 2022 (confirmed case in Portugal): Virological; 2022 [24 June 2022]. Available from:
    1. Lai A, Bergna A, Ventura CD, et al. First Monkeypox genome sequence from Italy: Virological; 2022 [24 June 2022]. Available from:
    1. Buenestado-Serrano S, Palomino-Cabrera R, Peñas-Utrilla D, et al. UPDATE: Two draft genomes from Madrid, Spain, of the Monkeypox virus 2022 outbreak: Virological; 2022 [24 June 2022]. Available from:
    1. Kumar N, Acharya A, Gendelman HE, et al. . The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun. 2022;131:102855.
    1. Peck KM, Lauring AS.. Complexities of viral mutation rates. J Virol. 2018;92(14):e01031-17.
    1. Cho CT, Wenner HA.. Monkeypox virus. Bacteriol Rev. 1973;37(1):1–18.
    1. Haller SL, Peng C, McFadden G, et al. . Poxviruses and the evolution of host range and virulence. Infect Genet Evol. 2014;21:15–40.
    1. Weaver JR, Isaacs SN.. Monkeypox virus and insights into its immunomodulatory proteins. Immunol Rev. 2008;225:96–113.
    1. Foo CH, Lou H, Whitbeck JC, et al. . Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology. 2009;385(2):368–382.
    1. Bisht H, Weisberg AS, Moss B.. Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol. 2008;82(17):8687–8694.
    1. Ravanello MP, Hruby DE.. Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly. J Virol. 1994;68(10):6401–6410.
    1. Hsiao JC, Chung CS, Chang W.. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol. 1999;73(10):8750–8761.
    1. Lin CL, Chung CS, Heine HG, et al. . Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol. 2000;74(7):3353–3365.
    1. Vanderplasschen A, Hollinshead M, Smith GL.. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol. 1998;79(Pt 4):877–887.
    1. Locker JK, Kuehn A, Schleich S, et al. . Entry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEV. Mol Biol Cell. 2000;11(7):2497–2511.
    1. Haywood AM. Membrane uncoating of intact enveloped viruses. J Virol. 2010;84(21):10946–10955.
    1. Moss B. Poxvirus DNA replication. Cold Spring Harb Perspect Biol. 2013;5(9):a010199.
    1. Kmiec D, Kirchhoff F.. Monkeypox: a new threat? Int J Mol Sci. 2022;23(14):7866.
    1. Akazawa D, Ohashi H, Hishiki T, et al. Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. bioRxiv. 2022.
    1. McFadden G. Poxvirus tropism. Nat Rev Microbiol. 2005;3(3):201–213.
    1. Falcinelli SD, Ciric J, Kindrachuk J.. Variola virus: clinical, molecular, and bioterrorism perspectives. In: Singh SK, Kuhn JH, editor. Defense against biological attacks: volume II. Cham: Springer International Publishing; 2019. p. 55–102.
    1. Wenner HA, Bolano CR, Cho CT, et al. . Studies on the pathogenesis of monkey pox. 3. Histopathological lesions and sites of immunofluorescence. Arch Gesamte Virusforsch. 1969;27(2):179–197.
    1. Hutson CL, Damon IK.. Monkeypox virus infections in small animal models for evaluation of anti-poxvirus agents. Viruses. 2010;2(12):2763–2776.
    1. Alakunle E, Moens U, Nchinda G, et al. . Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses. 2020;12(11):1257.
    1. Marennikova SS, Seluhina EM.. Susceptibility of some rodent species to monkeypox virus, and course of the infection. Bull World Health Organ. 1976;53(1):13–20.
    1. Dales S. The uptake and development of vaccinia virus in strain L cells followed with labeled viral deoxyribonucleic acid. J Cell Biol. 1963;18(1):51–72.
    1. Sheek MR, Magee WE.. An autoradiographic study on the intracellular development of vaccinia virus. Virology. 1961;15(2):146–163.
    1. Sauer R, Prier J, Buchanan R, et al. . Studies on a pox disease of monkeys. I. Pathology. Am J Vet Res. 1960;21:377–380.
    1. Hahon N. Cytopathogenicity and propagation of variola virus in tissue culture. J Immunol. 1958;81(5):426–432.
    1. Pirsch JB, Mika LA, Purlson EH.. Growth characteristics of variola virus in tissue culture. J Infect Dis. 1963;113:170–178.
    1. Rouhandeh H, Engler R, Taher M, et al. . Properties of monkey pox virus. Arch Gesamte Virusforsch. 1967;20(3):363–373.
    1. Cho CT, Wenner HA.. In vitro growth characteristics of monkeypox virus. Exp Biol Med. 1972;139(3):916–920.
    1. McConnell SJ, Herman YF, Mattson DE, et al. . Monkey pox disease in irradiated cynomologous monkeys. Nature. 1962;195(4846):1128–1129.
    1. von Magnus P, Andersen EK, Petersen KB, et al. . A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 1959;46(2):156–176.
    1. Marennikova SS, Gurvich EB, Shelukhina EM.. Comparison of the properties of five pox virus strains isolated from monkeys. Arch Gesamte Virusforsch. 1971;33(3):201–210.
    1. Gispen R, Verlinde JD, Zwart P.. Histopathological and virological studies on monkeypox. Arch Gesamte Virusforsch. 1967;21(2):205–216.
    1. McConnell SJ, Spertzel RO, Huxsoll DL, et al. . Plaque morphology of monkeypox virus as an aid to strain identification. J Bacteriol. 1964;87:238–239.
    1. Cho CT, Bolano CR, Kamitsuka PS, et al. . Methisazone and monkey pox virus: studies in cell cultures, chick embryos, mice and monkeys. Am J Epidemiol. 1970;92(2):137–144.
    1. Mika LA, Pirsch JB.. Differentiation of variola from other members of the poxvirus group by the plaque technique. J Bacteriol. 1960;80:861–863.
    1. DuShane JK, Maginnis MS.. Human DNA virus exploitation of the MAPK-ERK cascade. Int J Mol Sci. 2019;20(14):3427.
    1. Greber UF. Signalling in viral entry. Cell Mol Life Sci. 2002;59(4):608–626.
    1. Krajcsi P, Wold WS.. Viral proteins that regulate cellular signalling. J Gen Virol. 1998;79(6):1323–1335.
    1. Bourquain D, Dabrowski PW, Nitsche A.. Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals virus-specific regulation of immune response genes. Virol J. 2013;10(1):1–13.
    1. Reading PC, Symons JA, Smith GL.. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol. 2003;170(3):1435–1442.
    1. Counago RM, Knapp KM, Nakatani Y, et al. . Structures of Orf virus chemokine binding protein in complex with host chemokines reveal clues to broad binding specificity. Structure. 2015;23(7):1199–1213.
    1. Bahar MW, Kenyon JC, Putz MM, et al. . Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog. 2008;4(1):e5.
    1. Tanino Y, Coombe DR, Gill SE, et al. . Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. J Immunol. 2010;184(5):2677–2685.
    1. Alejo A, Ruiz-Arguello MB, Ho Y, et al. . A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci USA. 2006;103(15):5995–6000.
    1. Liu R, Moss B.. Vaccinia virus C9 ankyrin repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state. J Virol. 2018;92(9):e00053-18.
    1. Bibeau-Poirier A, Gravel SP, Clément JF, et al. . Involvement of the IκB kinase (IKK)-related kinases tank-binding kinase 1/IKKi and cullin-based ubiquitin ligases in IFN regulatory factor-3 degradation. J Immunol. 2006;177(8):5059–5067.
    1. Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol. 2019;10:325.
    1. Colamonici OR, Domanski P, Sweitzer SM, et al. . Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α transmembrane signaling. J Biol Chem. 1995;270(27):15974–8.
    1. Alcami A, Smith GL.. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol. 1995;69(8):4633–4639.
    1. Oda S, Schröder M, Khan AR.. Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure. 2009;17(11):1528–1537.
    1. Kukhanova MK, Karpenko IL, Ivanov AV.. DEAD-box RNA helicase DDX3: functional properties and development of DDX3 inhibitors as antiviral and anticancer drugs. Molecules. 2020;25(4):1015.
    1. Saikruang W, Ang Yan Ping L, Abe H, et al. . The RNA helicase DDX3 promotes IFNB transcription via enhancing IRF-3/p300 holocomplex binding to the IFNB promoter. Sci Rep. 2022;12(1):3967.
    1. Meng X, Jiang C, Arsenio J, et al. . Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol. 2009;83(20):10627–10636.
    1. Bravo Cruz AG, Shisler JL.. Vaccinia virus K1 ankyrin repeat protein inhibits NF-κB activation by preventing RelA acetylation. J Gen Virol. 2016;97(10):2691–2702.
    1. Deng L, Zeng Q, Wang M, et al. . Suppression of NF-κB activity: a viral immune evasion mechanism. Viruses. 2018;10(8):409.
    1. Adli M, Merkhofer E, Cogswell P, et al. . IKKα and IKKβ each function to regulate NF-κB activation in the TNF-induced/canonical pathway. PLoS One. 2010;5(2):e9428.
    1. Tang Q, Chakraborty S, Xu G.. Mechanism of vaccinia viral protein B14–mediated inhibition of IκB kinase β activation. J Biol Chem. 2018;293(26):10344–10352.
    1. Liu K, Lemon B, Traktman P.. The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro. J Virol. 1995;69(12):7823–7834.
    1. Mann BA, Huang JH, Li P, et al. . Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J Interferon Cytokine Res. 2008;28(6):367–380.
    1. Kong XF, Ciancanelli M, Al-Hajjar S, et al. . A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood. 2010;116(26):5895–5906.
    1. Tolomeo M, Cavalli A, Cascio A.. STAT1 and its crucial role in the control of viral infections. Int J Mol Sci. 2022;23(8):4095.
    1. Stuart JH, Sumner RP, Lu Y, et al. . Vaccinia virus protein C6 inhibits type I IFN signalling in the nucleus and binds to the transactivation domain of STAT2. PLoS Pathog. 2016;12(12):e1005955.
    1. Steen HC, Nogusa S, Thapa RJ, et al. . Identification of STAT2 serine 287 as a novel regulatory phosphorylation site in type I interferon-induced cellular responses. J Biol Chem. 2013;288(1):747–758.
    1. Unterholzner L, Sumner RP, Baran M, et al. . Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 2011;7(9):e1002247.
    1. Zhu L, Li Y, Xie X, et al. . TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. Nat Cell Biol. 2019;21(12):1604–1614.
    1. Lysakova-Devine T, Keogh B, Harrington B, et al. . Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol. 2010;185(7):4261–4271.
    1. Rehm KE, Connor RF, Jones GJB, et al. . Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology. 2010;397(1):176–186.
    1. Hegde NR, Chevalier MS, Johnson DC.. Viral inhibition of MHC class II antigen presentation. Trends Immunol. 2003;24(5):278–285.
    1. Eduardo-Correia B, Martínez-Romero C, García-Sastre A, et al. . ISG15 is counteracted by vaccinia virus E3 protein and controls the proinflammatory response against viral infection. J Virol. 2014;88(4):2312–2318.
    1. Schulz O, Pichlmair A, Rehwinkel J, et al. . Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe. 2010;7(5):354–361.
    1. Koehler H, Cotsmire S, Langland J, et al. . Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3. Proc Natl Acad Sci USA. 2017;114(43):11506–11511.
    1. Rothan HA, Arora K, Natekar JP, et al. . Z-DNA-binding protein 1 is critical for controlling virus replication and survival in West Nile virus encephalitis. Front Microbiol. 2019;10:2089.
    1. Kuriakose T, Man SM, Malireddi RK, et al. . ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci Immunol. 2016;1(2):aag2045.
    1. Upton JW, Kaiser WJ, Mocarski ES.. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe. 2012;11(3):290–297.
    1. Gerlic M, Faustin B, Postigo A, et al. . Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci USA. 2013;110(19):7808–7813.
    1. Taabazuing CY, Griswold AR, Bachovchin DA.. The NLRP1 and CARD8 inflammasomes. Immunol Rev. 2020;297(1):13–25.
    1. Vande Walle L, Lamkanfi M.. Inflammasomes: caspase-1-activating platforms with critical roles in host defense. Front Microbiol. 2011;2:3.
    1. Postigo A, Cross JR, Downward J, et al. . Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. Cell Death Differ. 2006;13(10):1651–1662.
    1. Aoyagi M, Zhai D, Jin C, et al. . Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci. 2006;16(1):118–124.
    1. Cooray S, Bahar MW, Abrescia NGA, et al. . Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol. 2007;88(Pt 6):1656–1666.
    1. Karch J, Schips TG, Maliken BD, et al. . Autophagic cell death is dependent on lysosomal membrane permeability through Bax and Bak. Elife. 2017;6:e30543.
    1. Dai Y, Grant S.. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy. 2015;11(2):416–418.
    1. Lomonosova E, Chinnadurai G.. BH3-only proteins in apoptosis and beyond: an overview. Oncogene. 2008;27(1):S2–S19.
    1. Jeudy S, Wardrop KE, Alessi A, et al. . Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy. PLoS One. 2011;6(8):e22369.
    1. Yang H, Kim SK, Kim M, et al. . Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest. 2005;115(2):379–387.
    1. Wee P, Wang Z.. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52.
    1. Carlin CR. Role of EGF receptor regulatory networks in the host response to viral infections. Front Cell Infect Microbiol. 2022;11:820355.
    1. Beerli C, Yakimovich A, Kilcher S, et al. . Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility. Nat Microbiol. 2019;4(2):216–225.
    1. Johnston JB, McFadden G.. Poxvirus immunomodulatory strategies: current perspectives. J Virol. 2003;77(11):6093–6100.
    1. Johnston JB, McFadden G.. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol. 2004;6(8):695–705.
    1. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol. 2003;3(1):36–50.
    1. Kaler J, Hussain A, Flores G, et al. . Monkeypox: a comprehensive review of transmission, pathogenesis, and manifestation. Cureus. 2022;14(7):e26531.
    1. Johnson RF, Dyall J, Ragland DR, et al. . Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol. 2011;85(5):2112–2125.
    1. Hudson PN, Self J, Weiss S, et al. . Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS One. 2012;7(4):e35086.
    1. Song H, Josleyn N, Janosko K, et al. . Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions. PLoS One. 2013;8(10):e77804.
    1. Johnston SC, Johnson JC, Stonier SW, et al. . Cytokine modulation correlates with severity of monkeypox disease in humans. J Clin Virol. 2015;63:42–45.
    1. Song H, Sidney J, Wiseman RW, et al. . Characterizing monkeypox virus specific CD8+ T cell epitopes in rhesus macaques. Virology. 2013;447(1-2):181–186.
    1. Estep RD, Messaoudi I, O’Connor MA, et al. . Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol. 2011;85(18):9527–9542.
    1. Rubins KH, Hensley LE, Relman DA, et al. . Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus. PLoS One. 2011;6(1):e15615.
    1. Earl PL, Americo JL, Moss B.. Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response. J Virol. 2012;86(17):9105–9112.
    1. Fernandez de Marco MM, Alejo A, Hudson P, et al. . The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon. FASEB J. 2010;24(5):1479–1488.
    1. Hernáez B, Alonso-Lobo JM, Montanuy I, et al. . A virus-encoded type I interferon decoy receptor enables evasion of host immunity through cell-surface binding. Nat Commun. 2018;9(1):5440.
    1. Montanuy I, Alejo A, Alcami A.. Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses. FASEB J. 2011;25(6):1960–1971.
    1. Arndt WD, Cotsmire S, Trainor K, et al. . Evasion of the innate immune type I interferon system by monkeypox virus. J Virol. 2015;89(20):10489–10499.
    1. Ando J, Ngo MC, Ando M, et al. . Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy. 2020;22(11):642–652.
    1. Lopez-Castejon G, Brough D.. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22(4):189–195.
    1. Uszewski MK, Farries TC, Lublin DM, et al. . Control of the complement system. Adv Immunol. 1996;61:201–283.
    1. Jones JM, Messauodi I, Estep RD, et al. . Monkeypox virus viral chemokine inhibitor (MPV vCCI), a potent inhibitor of rhesus macrophage inflammatory protein-1. Cytokine. 2008;43(2):220–228.
    1. Kindrachuk J, Arsenault R, Kusalik A, et al. . Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus. Mol Cell Proteomics. 2012;11(6):M111.015701.
    1. Hammarlund E, Dasgupta A, Pinilla C, et al. . Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proc Natl Acad Sci USA. 2008;105(38):14567–14572.
    1. Alzhanova D, Hammarlund E, Reed J, et al. . T cell inactivation by poxviral B22 family proteins increases viral virulence. PLoS Pathog. 2014;10(5):e1004123.
    1. Lopera JG, Falendysz EA, Rocke TE, et al. . Attenuation of monkeypox virus by deletion of genomic regions. Virology. 2015;475:129–138.
    1. Fenner F. Smallpox, “the most dreadful scourge of the human species.” Its global spread and recent eradication. Med J Aust. 1984;141(12-13):841–846.
    1. Parker S, Nuara A, Buller RML, et al. . Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007;2:17–34.
    1. Monkeypox: WHO; 2022 [19 June 2022]. Available from:
    1. Petersen E, Kantele A, Koopmans M, et al. . Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin. 2019;33(4):1027–1043.
    1. Brown K, Leggat PA.. Human monkeypox: current state of knowledge and implications for the future. Trop Med Infect Dis. 2016;1(1):8.
    1. Nolen LD, Osadebe L, Katomba J, et al. . Introduction of monkeypox into a community and household: risk factors and zoonotic reservoirs in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2015;93(2):410–415.
    1. Jezek Z, Szczeniowski M, Paluku KM, et al. . Human monkeypox: confusion with chickenpox. Acta Trop. 1988;45(4):297–307.
    1. Weese JS, Fulford MF.. Companion animal zoonoses. Oxford: Wiley-Blackwell; 2010.
    1. Monkeypox: CDC; [28 June 2022]. Available from:
    1. McCollum AM, Damon IK.. Human monkeypox. Clin Infect Dis. 2014;58(2):260–267.
    1. Roess AA, Monroe BP, Kinzoni EA, et al. . Assessing the effectiveness of a community intervention for monkeypox prevention in the Congo basin. PLoS Negl Trop Dis. 2011;5(10):e1356.
    1. Damon IK. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine. 2011;29(Suppl 4):D54–D59.
    1. Osadebe L, Hughes CM, Shongo Lushima R, et al. . Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo. PLoS Negl Trop Dis. 2017;11(9):e0005857.
    1. Jezek Z, Grab B, Szczeniowski MV, et al. . Human monkeypox: secondary attack rates. Bull World Health Organ. 1988;66(4):465–470.
    1. Lofquist JM, Weimert NA, Hayney MS.. Smallpox: a review of clinical disease and vaccination. Am J Health Syst Pharm. 2003;60(8):749–756; quiz 757–758.
    1. Bartlett J, Borio L, Radonovich L, et al. . Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis. 2003;36(7):883–902.
    1. Breman JG. Monkeypox: an emerging infection for humans? In: Scheld WM, Craig WA, Hughes JM, editor. Emerging Infections. Washington (DC: ): ASM Press; 2000. p. 45–67.
    1. Xiao SY, Sbrana E, Watts DM, et al. . Experimental infection of prairie dogs with monkeypox virus. Emerg Infect Dis. 2005;11(4):539–545.
    1. Tesh RB, Watts DM, Sbrana E, et al. . Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg Infect Dis. 2004;10(9):1563–1567.
    1. Breman JG, Kalisa R, Steniowski MV, et al. . Human monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165–182.
    1. Reynolds MG, Carroll DS, Karem KL.. Factors affecting the likelihood of monkeypox’s emergence and spread in the post-smallpox era. Curr Opin Virol. 2012;2(3):335–343.
    1. Jezek Z, Fenner F.. Human monkeypox. Basel, Switzerland: Karger Publishers; 1988.
    1. Breman JG, Bernadou J, Nakano JH.. Poxvirus in West African nonhuman primates: serological survey results. Bull World Health Organ. 1977;55(5):605–612.
    1. Bankuru SV, Kossol S, Hou W, et al. . A game-theoretic model of monkeypox to assess vaccination strategies. PeerJ. 2020;8:e9272.
    1. Mukinda VB, Mwema G, Kilundu M, et al. . Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group. Lancet. 1997;349(9063):1449–1450.
    1. Kabuga AI, El Zowalaty ME.. A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria. J Med Virol. 2019;91(4):533–540.
    1. Nasir IA, Dangana A, Ojeamiren I, et al. . Reminiscing the recent incidence of monkeypox in Nigeria: its ecologic-epidemiology and literature review. Port Harcourt Med J. 2018;12(1):1.
    1. Sadeuh-Mba SA, Yonga MG, Els M, et al. . Monkeypox virus phylogenetic similarities between a human case detected in Cameroon in 2018 and the 2017-2018 outbreak in Nigeria. Infect Genet Evol. 2019;69:8–11.
    1. Ogoina D, Izibewule JH, Ogunleye A, et al. . The 2017 human monkeypox outbreak in Nigeria—report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS One. 2019;14(4):e0214229.
    1. Nolen LD, Osadebe L, Katomba J, et al. . Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerg Infect Dis. 2016;22(6):1014–1021.
    1. Yinka-Ogunleye A, Aruna O, Ogoina D, et al. . Reemergence of human monkeypox in Nigeria, 2017. Emerg Infect Dis. 2018;24(6):1149–1151.
    1. Nalca A, Rimoin AW, Bavari S, et al. . Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005;41(12):1765–1771.
    1. Reynolds MG, Yorita KL, Kuehnert MJ, et al. . Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis. 2006;194(6):773–780.
    1. Fleischauer AT, Kile JC, Davidson M, et al. . Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis. 2005;40(5):689–694.
    1. Arita I, Jezek Z, Khodakevich L, et al. . Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa. Am J Trop Med Hyg. 1985;34(4):781–789.
    1. Durski KN, McCollum AM, Nakazawa Y, et al. . Emergence of monkeypox — West and Central Africa, 1970–2017. MMWR Morb Mortal Wkly Rep. 2018;67(10):306–310.
    1. Factsheet for health professionals on monkeypox: European Centre for Disease Prevention and Control; [25 June 2022]. Available from:
    1. Bernard SM, Anderson SA.. Qualitative assessment of risk for monkeypox associated with domestic trade in certain animal species, United States. Emerg Infect Dis. 2006;12(12):1827–1833.
    1. Hoff NA, Doshi RH, Colwell B, et al. . Evolution of a disease surveillance system: an increase in reporting of human monkeypox disease in the Democratic Republic of the Congo, 2001–2013. Int J Trop Dis Health. 2017;25(2):IJTDH.35885.
    1. Bunge EM, Hoet B, Chen L, et al. . The changing epidemiology of human monkeypox—a potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.
    1. Liu X, Zhu Z, He Y, et al. . Monkeypox claims new victims: the outbreak in men who have sex with men. Infect Dis Poverty. 2022;11(1):84.
    1. Khaity A, Hasan H, Albakri K, et al. . Monkeypox from Congo 1970 to Europe 2022; is there a difference?-Correspondence. Int J Surg. 2022;104:106827.
    1. Bragazzi NL, Kong JD, Mahroum N, et al. . Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review. J Med Virol. 2022. 10.1002/jmv.27931
    1. Inigo Martinez J, Gil Montalban E, Jimenez Bueno S, et al. . Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. Euro Surveill. 2022;27(27):2200471.
    1. Davido B, D’Anglejan E, Jourdan J, et al. . Monkeypox 2022 outbreak: cases with exclusive genital lesions. J Travel Med. 2022;29(6):taac077.
    1. Basgoz N, Brown CM, Smole SC, et al. . Case 24-2022: a 31-year-old man with perianal and penile ulcers, rectal pain, and rash. N Engl J Med. 2022;387(6):547–556.
    1. Patrocinio-Jesus R, Peruzzu F.. Monkeypox genital lesions. N Engl J Med. 2022;387(1):66.
    1. Patel A, Bilinska J, Tam JCH, et al. . Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. Br Med J. 2022;378:e072410.
    1. Perez Duque M, Ribeiro S, Martins JV, et al. . Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill. 2022;27(22):2200424.
    1. Antinori A, Mazzotta V, Vita S, et al. . Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill. 2022;27(22):2200421.
    1. Ortiz-Martinez Y, Zambrano-Sanchez G, Rodriguez-Morales AJ.. Monkeypox and HIV/AIDS: when the outbreak faces the epidemic. Int J STD AIDS. 2022;33(10):949–950.
    1. de Sousa D, Patrocinio J, Frade J, et al. . Human monkeypox coinfection with acute HIV: an exuberant presentation. Int J STD AIDS. 2022;33(10):936–938.
    1. Yinka-Ogunleye A, Aruna O, Dalhat M, et al. . Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872–879.
    1. Ogoina D, Iroezindu M, James HI, et al. . Clinical course and outcome of human monkeypox in Nigeria. Clin Infect Dis. 2020;71(8):e210–e214.
    1. Boesecke C, Monin MB, van Bremen K, et al. . Severe monkeypox-virus infection in undiagnosed advanced HIV infection. Infection. 2022. 10.1007/s15010-022-01901-z
    1. Rimoin AW, Mulembakani PM, Johnston SC, et al. . Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA. 2010;107(37):16262–16267.
    1. Monkeypox - United States of America: WHO; [20 June 2022]. Available from:
    1. Beer EM, Rao VB.. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019;13(10):e0007791.
    1. CDC . Human monkeypox – Kasai oriental, Democratic Republic of Congo, February 1996-October 1997. MMWR. 1997;46(49):1168–1171.
    1. Laudisoit A, Komba M, Akonda IJD. Scientific report research bushmeat and monkeypox Yahuma health zone–Aketi health zone-Bombongolo health area. 2016.
    1. WHO. Monkeypox - Democratic Republic of the Congo 2020 [5 July 2022]. Available from:
    1. Berthet N, Nakouné E, Whist E, et al. . Maculopapular lesions in the Central African Republic. Lancet. 2011;378(9799):1354.
    1. Nakoune E, Lampaert E, Ndjapou SG, et al. . A nosocomial outbreak of human monkeypox in the Central African Republic. Open Forum Infect Dis. 2017;4(4):ofx168.
    1. Kalthan E, Tenguere J, Ndjapou SG, et al. . Investigation of an outbreak of monkeypox in an area occupied by armed groups, Central African Republic. Med Mal Infect. 2018;48(4):263–268.
    1. WHO . Monkeypox - Central African Republic 2016 [5 July 2022]. Available from:
    1. WHO . Monkeypox - Cameroon 2018 [5 July 2022]. Available from: ).
    1. Learned LA, Reynolds MG, Wassa DW, et al. . Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg. 2005;73(2):428–434.
    1. Reynolds MG, Emerson GL, Pukuta E, et al. . Detection of human monkeypox in the Republic of the Congo following intensive community education. Am J Trop Med Hyg. 2013;88(5):982–985.
    1. Formenty P, Muntasir MO, Damon I, et al. . Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerg Infect Dis. 2010;16(10):1539–1545.
    1. Tchokoteu PF, Kago I, Tetanye E, et al. . [Variola or a severe case of varicella? A case of human variola due to monkeypox virus in a child from the Cameroon]. Ann Soc Belg Med Trop. 1991;71(2):123–128.
    1. Müller G, Meyer A, Gras F, et al. . Monkeypox virus in liver and spleen of child in Gabon. Lancet. 1988;331(8588):769–770.
    1. Breman JG, Nakano JH, Coffi E, et al. . Human poxvirus disease after smallpox eradication. Am J Trop Med Hyg. 1977;26(2):273–281.
    1. Reed KD, Melski JW, Graham MB, et al. . The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350(4):342–350.
    1. Sejvar JJ, Chowdary Y, Schomogyi M, et al. . Human monkeypox infection: a family cluster in the midwestern United States. J Infect Dis. 2004;190(10):1833–1840.
    1. WHO. Multi-country monkeypox outbreak: situation update 2022 [5 July 2022]. Available from:
    1. Vaughan A, Aarons E, Astbury J, et al. . Human-to-human transmission of monkeypox virus, United Kingdom, October 2018. Emerg Infect Dis. 2020;26(4):782–785.
    1. Monkeypox case confirmed in England: ; [22 June 2022]. Available from:
    1. Hobson G, Adamson J, Adler H, et al. . Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill. 2021;26(32):2100745.
    1. Yong SEF, Ng OT, Ho ZJM, et al. . Imported monkeypox, Singapore. Emerg Infect Dis. 2020;26(8):1826–1830.
    1. Adegboye OA, Eugenia Castellanos M, Alele FO, et al. . Travel-related monkeypox outbreaks in the era of COVID-19 pandemic: are we prepared? Viruses. 2022;14(6):1283.
    1. 2022 Monkeypox Outbreak Global Map: CDC; [7 August 2022]. Available from:
    1. Fauci AS. Emerging and reemerging infectious diseases: the perpetual challenge. Acad Med. 2005;80(12):1079–1085.
    1. Mahase E. Seven monkeypox cases are confirmed in England. Br Med J. 2022;377:o1239.
    1. Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication Geneva: World Health Organization; 1988 [updated 1988;05 September 2022]. Available from:
    1. Li Y, Olson VA, Laue T, et al. . Detection of monkeypox virus with real-time PCR assays. J Clin Virol. 2006;36(3):194–203.
    1. Karem KL, Reynolds M, Braden Z, et al. . characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol. 2005;12(7):867–872.
    1. Hutson CL, Gallardo-Romero N, Carroll DS, et al. . Transmissibility of the monkeypox virus clades via respiratory transmission: investigation using the prairie dog-monkeypox virus challenge system. PLoS One. 2013;8(2):e55488.
    1. Bayer-Garner IB. Monkeypox virus: histologic, immunohistochemical and electron-microscopic findings. J Cutan Pathol. 2005;32(1):28–34.
    1. Zaucha GM, Jahrling PB, Geisbert TW, et al. . The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest. 2001;81(12):1581–1600.
    1. Stagles MJ, Watson AA, Boyd JF, et al. . The histopathology and electron microscopy of a human monkeypox lesion. Trans R Soc Trop Med Hyg. 1985;79(2):192–202.
    1. Goff AJ, Chapman J, Foster C, et al. . A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol. 2011;85(10):4898–4909.
    1. Hutson CL, Carroll DS, Gallardo-Romero N, et al. . Comparison of monkeypox virus clade kinetics and pathology within the prairie dog animal model using a serial sacrifice study design. Biomed Res Int. 2015;2015:965710.
    1. Hazelton PR, Gelderblom HR.. Electron microscopy for rapid diagnosis of emerging infectious agents. Emerg Infect Dis. 2003;9(3):294–303.
    1. Barnhill RL. Textbook of dermatopathology. New York: McGraw-Hill Professional Publishing; 1998.
    1. Centers for Disease Control Prevention . Update: multistate outbreak of monkeypox–Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(27):642–646.
    1. Technical Advisory Group on Human Monkeypox: report of a WHO meeting, Geneva, Switzerland, 11-12 January 1999 Geneva: World Health Organization; 1999 [updated 1999;28 June 2022]. Available from:
    1. Jordan R, Leeds JM, Tyavanagimatt S, et al. . Development of ST-246® for treatment of poxvirus infections. Viruses. 2010;2(11):2409–2435.
    1. Centers for Disease Control Prevention . Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(19):532–536.
    1. Petersen BW, Damon IK, Pertowski CA, et al. . Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep. 2015;64(RR-02):1–26.
    1. Greenberg RN, Overton ET, Haas DW, et al. . Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis. 2013;207(5):749–758.
    1. World Health Organization . Identifying and responding to serious adverse events following immunization, following use of smallpox vaccine during a public health emergency: a guidance document for smallpox vaccine safety surveillance. Geneva: World Health Organization; 2018.
    1. Nalca A, Zumbrun EE.. ACAM2000™: the new smallpox vaccine for United States strategic national stockpile. Drug Des Devel Ther. 2010;4:71–79.
    1. Hutson CL, Kondas AV, Mauldin MR, et al. . Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. mSphere. 2021;6(1):e00927-20.
    1. Berhanu A, Prigge JT, Silvera PM, et al. . Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob Agents Chemother. 2015;59(7):4296–4300.
    1. Russo AT, Berhanu A, Bigger CB, et al. . Co-administration of tecovirimat and ACAM2000™ in non-human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2020;38(3):644–654.
    1. Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antiviral Chem Chemother. 2008;19(3):115–124.
    1. Baker RO, Bray M, Huggins JW.. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003;57(1-2):13–23.
    1. De Clercq E, Neyts J.. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev Med Virol. 2004;14(5):289–300.
    1. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002;55(1):1–13.
    1. Andrei G, Snoeck R.. Cidofovir activity against poxvirus infections. Viruses. 2010;2(12):2803–2830.
    1. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev. 2001;14(2):382–397.
    1. Stittelaar KJ, Neyts J, Naesens L, et al. . Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 2006;439(7077):745–748.
    1. McSharry JJ, Deziel MR, Zager K, et al. . Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother. 2009;53(1):129–135.
    1. Quenelle DC, Collins DJ, Kern ER.. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother. 2003;47(10):3275–3280.
    1. Duraffour S, Andrei G, Snoeck R.. New therapeutic weapons against poxvirus. Virology. 2008;12:323–338.
    1. Song H, Janosko K, Johnson RF, et al. . Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates. PLoS One. 2013;8(4):e60533.
    1. Smee DF, Sidwell RW, Kefauver D, et al. . Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother. 2002;46(5):1329–1335.
    1. Wei H, Huang D, Fortman J, et al. . Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol. 2009;83(2):1115–1125.
    1. Quenelle DC, Collins DJ, Herrod BP, et al. . Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother. 2007;51(11):3940–3947.
    1. Parker S, Schriewer J, Oberle C, et al. . Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir Ther. 2008;13(7):863–873.
    1. Rice AD, Adams MM, Lampert B, et al. . Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3(2):63–82.
    1. Stabenow J, Buller RM, Schriewer J, et al. . A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol. 2010;84(8):3909–3920.
    1. Rice AD, Adams MM, Wallace G, et al. . Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3(1):47–62.
    1. Duraffour S, Andrei G, Snoeck R.. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs. 2010;13(3):181–191.
    1. Priyamvada L, Alabi P, Leon A, et al. . Discovery of Retro-1 analogs exhibiting enhanced anti-vaccinia virus activity. Front Microbiol. 2020;11:603.
    1. Vigne S, Duraffour S, Andrei G, et al. . Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir. Antimicrob Agents Chemother. 2009;53(6):2579–2588.
    1. Alkhalil A, Strand S, Mucker E, et al. . Inhibition of monkeypox virus replication by RNA interference. Virol J. 2009;6:188.
    1. Vigne S, Germi R, Duraffour S, et al. . Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting theD5R gene. Antivir Ther. 2008;13(3):357–368.
    1. Smee DF, Bray M, Huggins JW.. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem Chemother. 2001;12(6):327–335.
    1. Kunasekaran MP. Report of monkeypox cases in 2018 in the United Kingdom. Global Biosecurity. 2019;1(1):140.
    1. Karem KL, Reynolds M, Hughes C, et al. . Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol. 2007;14(10):1318–1327.
    1. Hooper JW, Thompson E, Wilhelmsen C, et al. . Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol. 2004;78(9):4433–4443.
    1. Keasey S, Pugh C, Tikhonov A, et al. . Proteomic basis of the antibody response to monkeypox virus infection examined in cynomolgus macaques and a comparison to human smallpox vaccination. PLoS One. 2010;5(12):e15547.
    1. Xiao Y, Isaacs SN.. Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections. Viruses. 2010;2(10):2381–2403.
    1. Heraud JM, Edghill-Smith Y, Ayala V, et al. . Subunit recombinant vaccine protects against monkeypox. J Immunol. 2006;177(4):2552–2564.
    1. Stittelaar KJ, van Amerongen G, Kondova I, et al. . Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol. 2005;79(12):7845–7851.
    1. Albarnaz JD, Torres AA, Smith GL.. Modulating vaccinia virus immunomodulators to improve immunological memory. Viruses. 2018;10(3):101.
    1. Hashizume S, Yoshizawa H, Morita M, et al. . Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Quinnan GV, editor. Vaccinia viruses as vectors for vaccine antigens. New York (NY: ): Elsevier Science Publishing Co.; 1985. p. 87–99.
    1. Takahashi-Nishimaki F, Funahashi S, Miki K, et al. . Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology. 1991;181(1):158–164.
    1. Johnson BF, Kanatani Y, Fujii T, et al. . Serological responses in humans to the smallpox vaccine LC16m8. J Gen Virol. 2011;92(Pt 10):2405–2410.
    1. Putz MM, Midgley CM, Law M, et al. . Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med. 2006;12(11):1310–1315.
    1. Saijo M, Ami Y, Suzaki Y, et al. . LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol. 2006;80(11):5179–5188.
    1. Smallpox Vaccine Supply & Strength: National Institute of Allergy and Infectious Diseases; [28 June 2022]. Available from:
    1. Meseda CA, Garcia AD, Kumar A, et al. . Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology. 2005;339(2):164–175.
    1. Wyatt LS, Earl PL, Eller LA, et al. . Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA. 2004;101(13):4590–4595.
    1. Davies DH, Wyatt LS, Newman FK, et al. . Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J Virol. 2008;82(2):652–663.
    1. Hatch GJ, Graham VA, Bewley KR, et al. . Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol. 2013;87(14):7805–7815.
    1. Volz A, Sutter G.. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res. 2017;97:187–243.
    1. Meyer H, Sutter G, Mayr A.. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991;72(Pt 5):1031–1038.
    1. Antoine G, Scheiflinger F, Dorner F, et al. . The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 1998;244(2):365–396.
    1. Sutter G, Moss B.. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992;89(22):10847–10851.
    1. Blanchard TJ, Alcami A, Andrea P, et al. . Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol. 1998;79(Pt 5):1159–1167.
    1. Nájera JL, Gómez CE, Domingo-Gil E, et al. . Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol. 2006;80(12):6033–6047.
    1. Paoletti E, Tartaglia J, Taylor J.. Safe and effective poxvirus vectors–NYVAC and ALVAC. Dev Biol Stand. 1994;82:65–69.
    1. Tartaglia J, Cox WI, Pincus S, et al. . Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand. 1994;82:125–129.
    1. Tartaglia J, Perkus ME, Taylor J, et al. . NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992;188(1):217–232.
    1. Keckler MS, Salzer JS, Patel N, et al. . IMVAMUNE® and ACAM2000® provide different protection against disease when administered postexposure in an intranasal monkeypox challenge prairie dog model. Vaccines (Basel). 2020;8(3):396.

Source: PubMed

3
Abonnieren